A carregar...
Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma
BACKGROUND: Patients with severe, uncontrolled asthma experience debilitating symptoms that result in meaningful reductions to health-related quality of life. Benralizumab is an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody that reduces exacerbations and improves asthma symptom...
Na minha lista:
| Publicado no: | J Asthma Allergy |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6350639/ https://ncbi.nlm.nih.gov/pubmed/30774388 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JAA.S190221 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|